title: Safety and immunogenicity of a Proteosome -trivalent inactivated influenza vaccine, given nasally to healthy adults.
abstract: We studied the safety and immunogenicity of a nasally administered vaccine comprising three monovalent inactivated influenza antigens (A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Guangdong/120/2000) non-covalently associated with outer membrane proteins of Neisseria meningitidis (Proteosome) in normal, healthy adults. In a randomized, double-blind trial participants (n = 78) were allocated to placebo or a single nasal dose of vaccine containing 15, 30, or 45 microg of each of the three HA antigens, or two nasal doses containing 30 microg of each HA, separated by 2 weeks. The vaccine was generally well tolerated in all doses tested, and in a one or two-dose schedule. A shallow vaccine reactogenicity dose-response was seen. The most common local reaction was nasal congestion, which occurred in up to 48.3% of vaccine recipients in days 0-6 after vaccine but was mild and self-limiting; this reaction was not significantly more common among active vaccine recipients than placebo recipients. Mild to moderate headache was the most commonly reported systemic reactogenicity complaint in all treatment groups, and was the only solicited complaint to increase significantly in frequency after a second active dose. No severe systemic reactions occurred. A positive and statistically significant antibody response was observed, in serum and in nasal secretions, to increasing dose for all three antigens. Serum HAI titre responses and nasal secretory IgA immune responses were elicited against all three antigens. Further testing of this nasal influenza vaccine is warranted to determine its safety and immunogenicity in these populations and its efficacy in the prevention of clinical illness.
authors.affiliation: Division of Infectious Diseases, Department of Pediatrics, Dalhousie University, Halifax, NS, Canada. Joanne.Langley@dal.ca
authors.forename: Joanne M
authors.initials: JM
authors.lastname: Langley
authors.forename: Scott A
authors.initials: SA
authors.lastname: Halperin
authors.forename: Shelly
authors.initials: S
authors.lastname: McNeil
authors.forename: Bruce
authors.initials: B
authors.lastname: Smith
authors.forename: Taff
authors.initials: T
authors.lastname: Jones
authors.forename: David
authors.initials: D
authors.lastname: Burt
authors.forename: Corey P
authors.initials: CP
authors.lastname: Mallett
authors.forename: George H
authors.initials: GH
authors.lastname: Lowell
authors.forename: Louis
authors.initials: L
authors.lastname: Fries
mesh_terms: D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D001425:Bacterial Outer Membrane Proteins / Q000008:administration & dosage*; D004311:Double-Blind Method; D016503:Drug Delivery Systems; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D008875:Middle Aged; D049329:Nanostructures; D012449:Safety; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology
chemical_list: D001425:Bacterial Outer Membrane Proteins; D007252:Influenza Vaccines; D015164:Vaccines, Inactivated